Nitric oxide is produced by nitric oxide synthases using L-arginine as substrate, and it acts on smooth muscle to promote vasodilation via cyclic guanosine monophosphate. The study team observed that these signaling pathways extend into the kidney where NO contributes to renal hemodynamic regulation, glomerular filtration, tubular processes, and microcirculatory homeostasis. Early clinical practice treated inhaled nitric oxide as a selective pulmonary vasodilator with only local effects in the lung, but data examined in this review challenge that narrow view. The authors noted that systemic renal processes may be affected indirectly — through changes in pulmonary hemodynamics, redistribution of blood flow, or by circulating NO metabolites — though exact pathways vary by clinical context and are incompletely described in existing reports.
The review framed the kidney impact of inhaled therapy as a balance. On one hand, investigators reported potential benefit when inhaled delivery restores NO bioavailability in settings of NO depletion or scavenging. On the other hand, data indicated that oxidative and nitrosative stress generated during or after inhalation can offset favourable signaling and harm renal tissue. The authors emphasized that net effect depends on competing mechanisms: improved NO-mediated vasodilation and microvascular perfusion versus increased reactive nitrogen species and oxidative injury. The review did not provide novel experimental dosing or mechanistic measurements; rather, it integrated published mechanistic reasoning with clinical outcome signals identified in heterogeneous studies.
Clinical evidence in ARDS was singled out in the review. The study team reported that higher-level evidence suggests a potential increase in acute kidney injury associated with inhaled nitric oxide in this population. The review linked this signal to pathways of oxidative and nitrosative stress that may be amplified in ARDS physiology, although authors cautioned that heterogeneity in study designs and endpoints complicates interpretation. The available literature used different patient populations and renal outcome definitions; the review noted that most prior work focused on pulmonary endpoints rather than prespecified renal outcomes, leaving uncertainty about causality and magnitude of kidney risk.
In contrast to ARDS, the authors observed that inhaled nitric oxide may confer nephroprotection in the setting of cardiac bypass surgery. The review explained the proposed mechanism: during cardiopulmonary bypass, hemolysis and release of free hemoglobin can scavenge NO, reducing its bioavailability, and inhaled NO may restore that signalling. Clinical data assembled by the authors suggested beneficial renal effects in this context, though the report clarified that evidence strength and consistency vary between studies. As with other sections, the review did not supply new trial-level statistics within the abstract; it summarized directional findings across the literature and emphasized mechanistic plausibility for benefit in this surgical population.
For other critical-care indications — including organ transplantation, pulmonary hypertension, sepsis, and hemolytic disorders — the review team found the evidence limited or inconclusive. Investigators reported that available studies are sparse, often observational, and rarely designed with renal endpoints specified a priori. The authors noted that in these settings mechanisms could plausibly result in either harm or benefit depending on baseline NO bioavailability and the degree of oxidative stress, but current clinical data do not permit firm conclusions.
The review concluded that there is no uniform renal effect of inhaled nitric oxide across critically ill populations. Data indicated context dependence: a signal toward increased acute kidney injury in ARDS and potential nephroprotection in cardiac bypass surgery, with uncertainty elsewhere. The authors explicitly called for prospective studies that include predefined renal endpoints to clarify clinical relevance. They also pointed out that much of the existing literature prioritized pulmonary outcomes, leaving renal physiology and kidney-specific endpoints underexplored. The review did not report novel trial designs, dosing regimens, or specific sample sizes; those details were not provided in the abstract. The article ends on a practical research mandate rather than a broad clinical pronouncement: targeted, prospectively planned investigations with renal outcome measures are needed to resolve the divergent signals described.
Limitations noted by the review team include heterogeneity of published studies, differing renal endpoint definitions, and the predominance of investigations that were not designed to assess kidney outcomes prospectively. Those gaps define the immediate unanswered clinical questions: which patient subgroups derive renal benefit versus harm from inhaled nitric oxide, and what are the mechanistic biomarkers that should be measured in future trials to distinguish restorative NO signaling from injurious oxidative stress.